Prognosis
Smartphones, travel and mental health.
View in browser
Bloomberg

Prognosis is exclusively for Bloomberg.com subscribers. As a loyal reader, you’re receiving a complimentary trial. If you’d like to continue receiving Prognosis, and gain unlimited digital access to all of Bloomberg.com, we invite you to subscribe now at the special rate of $149 for your first year (usually $299).

Hello reader, it’s Lisa in London. I’ve been pondering whether hospitalizations linked to a rare (and much-debated) phenomenon known as Paris Syndrome still occur — but before we get to that…

Today’s must-reads

  • Boxer Floyd Mayweather’s latest side hustle is supplement salesman.
  • Blood cancer drug Blenrep gets US approval, a key milestone for GSK.
  • Heading to Shanghai? Jetlag doesn’t stand a chance against the city’s coffee scene. 

Travelers in Paris

My first visit to Paris in 2005 was also my first overseas solo trip. Back then, iPhones didn’t exist and the exorbitant cost of international roaming was out of my budget, meaning I was cut off from my day-to-day life at home in Australia. “Paris Syndrome” was still a niche concept, but awareness was starting to build. 

Coined in the 1980s by psychiatrist Hiroaki Ota, the term is used to describe the extreme culture shock that some Japanese travelers face when their experience of the French capital doesn’t live up to expectations. In the most severe cases, hospitalization and repatriation may be involved. 

Ota and his colleagues published a paper in 2004 that mentioned 63 Japanese nationals had been admitted to the Sainte-Anne psychiatric hospital in Paris since 1988. Some were in a delusional state, while others showed signs of major anxiety. Several patients had a history of mental disorders such as schizophrenia. 

Millions of Japanese tourists have visited Paris over the years, so the number of hospitalizations is quite minimal. It’s unclear whether hospital admissions linked to Paris Syndrome still occur and if so, to what extent. No comprehensive statistics are available beyond 2011, the year the Japanese language consultation service at Saint-Anne hospital closed, Ota wrote in a book published earlier this year. He retired in 2021, according to his book. 

Still, some people argue there isn’t necessarily anything unique about Paris or Japanese travelers. Being in a different environment can be stressful for many individuals. 

GHU Paris — the hospital group that includes Saint-Anne — told me they didn’t have any professionals available to respond to my hospitalization queries. “Furthermore, Paris Syndrome is still the subject of debate from an epidemiological, scientific, and pathological perspective,” a spokesperson said by email.

Meanwhile, the Japanese Embassy in France said their delegation was unable to assess potential cases of Paris Syndrome when I asked about repatriations. The embassy “always strives to provide the necessary support for any requests from travelers and nationals experiencing difficulties during their stay in France, including those with mental health issues,” according to an emailed response.    

The way people travel has changed since the research paper was published in 2004, in the French psychiatry journal Nervure. Tourists can now navigate cities with their smartphones, use Google Translate to communicate and keep in touch with friends and family in real time. The language barriers and feelings of isolation that are among the challenges linked to Paris Syndrome might not be as severe as they once were.

That said, unrealistic expectations are social media’s stock-in-trade. 

If travelers are already feeling “wobbly,” then smartphones “will make it harder, not easier,” says Nicolas Geeraert, an associate professor at the department of psychology at the University of Essex. When it comes to the glossiness of social media, “if you are expecting it to be awesome all the time and the reality isn’t like that, that is going to create some unease.” — Lisa Pham

The big story

The same Nobel prize-winning mRNA technology that helped curb the Covid-19 pandemic may be poised to transform cancer care, according to a new study published in the journal Nature. Patients with advanced lung or skin cancer who received a Covid-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who didn’t, the researchers found. 

The findings hint that vaccines developed to stop a virus may also bolster the immune system to fight cancer. They also come at a time when the future of mRNA research faces fresh political headwinds in the US, reports Bloomberg’s Jason Gale.

What we’re reading

Some medical students are opting to study in Bulgaria amid a cap on medical school places in the UK, the BBC reports

Members of Gen Z are “significantly” underrepresented in clinical trials and health studies, according to a data analysis by The Guardian. 

The Financial Times delves into the quest of turning young people’s blood into a drug to slow ageing. 

Contact Prognosis

Health questions? Have a tip that we should investigate? Contact us at AskPrognosis@bloomberg.net.

Follow Us

Like getting this newsletter? There's more where that came from. Browse all our weekly and daily emails to get even more insights from your Bloomberg.com subscription.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Prognosis newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices